Bavarian Nordic

Regulatory Filings • Sep 15, 2009

Company Announcement

15 September 2009

Bavarian Nordic has signed contract with an EU country for the delivery of IMVAMUNE®

Kvistgaard, Denmark, September has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE®. The vaccines will be delivered in 2009. The size and value of the contract is undisclosed. 15, 2009 – Bavarian Nordic A/S (OMX: BAVA) announced today that that it

This marks the first time, Bavarian Nordic IMVAMUNE®, and it demonstrates that there exists a real demand inside of EU for new and safer smallpox vaccines for preparedness stockpiles. enters a contract with an EU country for the delivery of

This contract does not affect the company's expectations for the 2009 full year results.

Anders Hedegaard, President & CEO of Bavarian Nordic said: country on IMVAMUNE® demonstrates continued ongoing positive dialogue with governments in and outside the EU will lead to several smaller contracts authorities to initiate the delivery of IMVAMUNE® under the RFP will be an important message to other said: "Entering the first contract with an EU the need for new and safer smallpox vaccines. We have a EU, and we expect that th contracts. When we expectedly receive the approval from the US RFP-3 contract for 20 million doses, this governments currently considering to stockpile IMVAMUNE®. this t IMVAMUNE®."

Asger Aamund Chairman

Contact Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

Forward-looking statements

This announcement includes "forwardwhich are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forwardfuture events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking state except as required by law. -looking statements" that involve risks, uncertainties and other factors, many of -looking statements include statements concerning our plans, objectives, goals, looking statements to reflect subsequent events or circumstances after the date made, looking looking ments generation

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUN with the US government, and PROSTVAC™, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute. threatening IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian avarian www.bavarian-nordic.com

Company Announcement no. Page 1 of 1 no. 22 / 2009

Bavarian Nordic A/S Hejreskovvej 10A

DK-3490 Kvistgaard Denmark 3490 Kvistgaard Fax: +45 33 26 83 80

10A Tel: +45 33 26 83 83 www.bavarian-nordic.com

nordic.com CVR-no: 16 27 11 87